Biodexa Pharmaceuticals PlcBDRX
Price (close)
$0.68
Market cap
—
P/E
—
Revenue (FY)
—
Net income
-$6.4M
Dividend yield
—
1-year total return
-98.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What Biodexa Pharmaceuticals Plc does.
are a clinical stage biopharmaceutical company developing a pipeline of innovative products focused on the treatment or prevention of
April 2024 we licensed eRapa, a proprietary formulation of rapamycin, from Rapamycin Holdings, Inc. d/b/a Emtora Biosciences, Inc., or
Emtora. Rapamycin is an mTOR inhibitor. As a central regulator of cell metabolism, growth, proliferation and survival, the mTOR pathway
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $343,000 | $578,000 | $699,000 | $381,000 | — | — |
| Net income | -$22.2M | -$5.5M | -$7.7M | -$7.1M | -$5.7M | -$6.4M |
| Free cash flow | -$9.5M | -$6.3M | -$7.1M | -$6.9M | -$12.3M | -$5.6M |
More on BDRX.
- Biodexa Pharmaceuticals Plc summary
- Biodexa Pharmaceuticals Plc financial statements
- Biodexa Pharmaceuticals Plc key metrics
- Biodexa Pharmaceuticals Plc health scores and style box
- Biodexa Pharmaceuticals Plc earnings
- Biodexa Pharmaceuticals Plc dividends
- Biodexa Pharmaceuticals Plc valuation
- Biodexa Pharmaceuticals Plc ownership and insiders
- Biodexa Pharmaceuticals Plc peers
Figures from Biodexa Pharmaceuticals Plc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.